_id
6911c809ccc777a4e85d662a
Ticker
HTDS
Name
Hard to Treat Diseases Inc
Exchange
OTCCE
Address
Room EF, 12F, Shenzhen, China, 518040
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.mellowhope.com
Description
Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.
Last Close
-
Volume
-
Current Price
0
Change
0
Last Updated
2026-01-04T14:45:14.160Z
Image
-
Ipo Date
-
Market Cap
109646
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2010-09-30
Revenue
509464
Cost Of Revenue
284252
Gross Profit
225212
Operating Expenses
421478
Operating Income
87986
Interest Expense
-
Pretax Income
87986
Net Income
87986
Eps
-
Dividends Per Share
-
Shares Outstanding
5482339840
Income Tax Expense
0
EBITDA
-
Operating Margin
17.270307617417522
Total Other Income Expense Net
0
Cash
202900
Short Term Investments
-
Receivables
1853690
Inventories
768872
Total Current Assets
3762380
Property Plant Equipment
82708
Total Assets
3845088
Payables
1148796
Short Term Debt
450450
Long Term Debt
-
Total Liabilities
1661321
Equity
2182767
Bs_currency_symbol
USD
Depreciation
15221
Change In Working Capital
-
Cash From Operations
95723
Capital Expenditures
9413
Cash From Investing
604507
Cash From Financing
-1643903
Net Change In Cash
-943673
Cf_currency_symbol
USD
PE
0
PB
-
ROE
4.030938712194201
ROA
2.2882701254171556
FCF
86310
Fcf Percent
0.16941334422059262
Piotroski FScore
4
Health Score
55
Deep Value Investing Score
5
Defensive Investing Score
6.5
Dividend Investing Score
3
Economic Moat Investing Score
8.8
Garp Investing Score
3.5
Growth Investing Score
2.5
Momentum Investing Score
5
Net Net Investing Score
9.5
Quality Investing Score
6
Value Investing Score
3
Quarters > 0 > quarter
2010-09-30
Quarters > 0 > income Statement > revenue
509464
Quarters > 0 > income Statement > cost Of Revenue
284252
Quarters > 0 > income Statement > gross Profit
225212
Quarters > 0 > income Statement > operating Expenses
421478
Quarters > 0 > income Statement > operating Income
87986
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
87986
Quarters > 0 > income Statement > net Income
87986
Quarters > 0 > income Statement > eps
-
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
-
Quarters > 0 > income Statement > income Tax Expense
0
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
17.270307617417522
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
202900
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
1853690
Quarters > 0 > balance Sheet > inventories
768872
Quarters > 0 > balance Sheet > total Current Assets
3762380
Quarters > 0 > balance Sheet > property Plant Equipment
82708
Quarters > 0 > balance Sheet > total Assets
3845088
Quarters > 0 > balance Sheet > payables
1148796
Quarters > 0 > balance Sheet > short Term Debt
450450
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
1661321
Quarters > 0 > balance Sheet > equity
2182767
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
87986
Quarters > 0 > cash Flow > depreciation
15221
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
95723
Quarters > 0 > cash Flow > capital Expenditures
9413
Quarters > 0 > cash Flow > cash From Investing
604507
Quarters > 0 > cash Flow > cash From Financing
-1643903
Quarters > 0 > cash Flow > net Change In Cash
-943673
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-
Quarters > 0 > ratios > PB
-
Quarters > 0 > ratios > ROE
4.030938712194201
Quarters > 0 > ratios > ROA
2.2882701254171556
Quarters > 0 > ratios > FCF
86310
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.16941334422059262
Quarters > 0 > health Score
55
Quarters > 1 > quarter
2010-06-30
Quarters > 1 > income Statement > revenue
659857
Quarters > 1 > income Statement > cost Of Revenue
371506
Quarters > 1 > income Statement > gross Profit
288351
Quarters > 1 > income Statement > operating Expenses
609811
Quarters > 1 > income Statement > operating Income
50046
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
50046
Quarters > 1 > income Statement > net Income
50046
Quarters > 1 > income Statement > eps
-
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
-
Quarters > 1 > income Statement > income Tax Expense
0
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
7.584370553013758
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
1146573
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
3238603
Quarters > 1 > balance Sheet > inventories
25365
Quarters > 1 > balance Sheet > total Current Assets
5348959
Quarters > 1 > balance Sheet > property Plant Equipment
88544
Quarters > 1 > balance Sheet > total Assets
5437503
Quarters > 1 > balance Sheet > payables
2087794
Quarters > 1 > balance Sheet > short Term Debt
1225500
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
3378944
Quarters > 1 > balance Sheet > equity
2057559
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
50046
Quarters > 1 > cash Flow > depreciation
9537
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
59583
Quarters > 1 > cash Flow > capital Expenditures
17506
Quarters > 1 > cash Flow > cash From Investing
2307886
Quarters > 1 > cash Flow > cash From Financing
-1590533
Quarters > 1 > cash Flow > net Change In Cash
776936
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-
Quarters > 1 > ratios > PB
-
Quarters > 1 > ratios > ROE
2.432299632720131
Quarters > 1 > ratios > ROA
0.9203856990975453
Quarters > 1 > ratios > FCF
42077
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.06376684645309515
Quarters > 1 > health Score
36
Quarters > 2 > quarter
2010-03-31
Quarters > 2 > income Statement > revenue
2164021
Quarters > 2 > income Statement > cost Of Revenue
1675049
Quarters > 2 > income Statement > gross Profit
488972
Quarters > 2 > income Statement > operating Expenses
1945329
Quarters > 2 > income Statement > operating Income
218692
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
218692
Quarters > 2 > income Statement > net Income
211208
Quarters > 2 > income Statement > eps
-
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
-
Quarters > 2 > income Statement > income Tax Expense
7484
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
10.105816902885877
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
369637
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
5546088
Quarters > 2 > balance Sheet > inventories
15536
Quarters > 2 > balance Sheet > total Current Assets
6868429
Quarters > 2 > balance Sheet > property Plant Equipment
80548
Quarters > 2 > balance Sheet > total Assets
6948977
Quarters > 2 > balance Sheet > payables
3472012
Quarters > 2 > balance Sheet > short Term Debt
1438489
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
4976081
Quarters > 2 > balance Sheet > equity
1971896
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
211208
Quarters > 2 > cash Flow > depreciation
12158
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
230850
Quarters > 2 > cash Flow > capital Expenditures
17506
Quarters > 2 > cash Flow > cash From Investing
-2226749
Quarters > 2 > cash Flow > cash From Financing
2165288
Quarters > 2 > cash Flow > net Change In Cash
169389
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-
Quarters > 2 > ratios > PB
-
Quarters > 2 > ratios > ROE
10.710909703148646
Quarters > 2 > ratios > ROA
3.0394114126439042
Quarters > 2 > ratios > FCF
213344
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.09858684365817152
Quarters > 2 > health Score
44
Quarters > 3 > quarter
2009-12-31
Quarters > 3 > income Statement > revenue
2825408
Quarters > 3 > income Statement > cost Of Revenue
2045119
Quarters > 3 > income Statement > gross Profit
780289
Quarters > 3 > income Statement > operating Expenses
2200348
Quarters > 3 > income Statement > operating Income
625060
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
625060
Quarters > 3 > income Statement > net Income
625060
Quarters > 3 > income Statement > eps
-
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
-
Quarters > 3 > income Statement > income Tax Expense
0
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
22.12282261535325
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
200248
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
3335125
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
4472291
Quarters > 3 > balance Sheet > property Plant Equipment
92705
Quarters > 3 > balance Sheet > total Assets
4564996
Quarters > 3 > balance Sheet > payables
1216095
Quarters > 3 > balance Sheet > short Term Debt
1543773
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
2792214
Quarters > 3 > balance Sheet > equity
1771782
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
625060
Quarters > 3 > cash Flow > depreciation
18555
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
643615
Quarters > 3 > cash Flow > capital Expenditures
24217
Quarters > 3 > cash Flow > cash From Investing
-2105237
Quarters > 3 > cash Flow > cash From Financing
1318072
Quarters > 3 > cash Flow > net Change In Cash
-143550
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-
Quarters > 3 > ratios > PB
-
Quarters > 3 > ratios > ROE
35.27860651028174
Quarters > 3 > ratios > ROA
13.69245449503132
Quarters > 3 > ratios > FCF
619398
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.2192242677871656
Quarters > 3 > health Score
72
Annuals > 0 > quarter
2009-12-31
Annuals > 0 > income Statement > revenue
5390107
Annuals > 0 > income Statement > cost Of Revenue
3972888
Annuals > 0 > income Statement > gross Profit
1417219
Annuals > 0 > income Statement > operating Expenses
4768506
Annuals > 0 > income Statement > operating Income
621601
Annuals > 0 > income Statement > interest Expense
0
Annuals > 0 > income Statement > pretax Income
621601
Annuals > 0 > income Statement > net Income
621601
Annuals > 0 > income Statement > eps
-
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
-
Annuals > 0 > income Statement > income Tax Expense
0
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
11.532257151852459
Annuals > 0 > income Statement > total Other Income Expense Net
0
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
200248
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
3335125
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
4472291
Annuals > 0 > balance Sheet > property Plant Equipment
92705
Annuals > 0 > balance Sheet > total Assets
4564996
Annuals > 0 > balance Sheet > payables
1216095
Annuals > 0 > balance Sheet > short Term Debt
1543773
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
2792214
Annuals > 0 > balance Sheet > equity
1771782
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
621601
Annuals > 0 > cash Flow > depreciation
34104
Annuals > 0 > cash Flow > change In Working Capital
-
Annuals > 0 > cash Flow > cash From Operations
655705
Annuals > 0 > cash Flow > capital Expenditures
24217
Annuals > 0 > cash Flow > cash From Investing
-1652986
Annuals > 0 > cash Flow > cash From Financing
930561
Annuals > 0 > cash Flow > net Change In Cash
-66720
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-
Annuals > 0 > ratios > PB
-
Annuals > 0 > ratios > ROE
35.083379332220325
Annuals > 0 > ratios > ROA
13.616682249009637
Annuals > 0 > ratios > FCF
631488
Annuals > 0 > ratios > Piotroski FScore
4
Annuals > 0 > ratios > fcf Percent
0.11715685792508386
Annuals > 0 > health Score
64
Annuals > 1 > quarter
1999-12-31
Annuals > 1 > income Statement > revenue
71562
Annuals > 1 > income Statement > cost Of Revenue
54385
Annuals > 1 > income Statement > gross Profit
17177
Annuals > 1 > income Statement > operating Expenses
0
Annuals > 1 > income Statement > operating Income
-971060
Annuals > 1 > income Statement > interest Expense
0
Annuals > 1 > income Statement > pretax Income
-1010110
Annuals > 1 > income Statement > net Income
-1010110
Annuals > 1 > income Statement > eps
-
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
-
Annuals > 1 > income Statement > income Tax Expense
0
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-1356.9492188591712
Annuals > 1 > income Statement > total Other Income Expense Net
-
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
9661
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
9354
Annuals > 1 > balance Sheet > inventories
343791
Annuals > 1 > balance Sheet > total Current Assets
374965
Annuals > 1 > balance Sheet > property Plant Equipment
182408
Annuals > 1 > balance Sheet > total Assets
714814
Annuals > 1 > balance Sheet > payables
550129
Annuals > 1 > balance Sheet > short Term Debt
303255
Annuals > 1 > balance Sheet > long Term Debt
81106
Annuals > 1 > balance Sheet > total Liabilities
934490
Annuals > 1 > balance Sheet > equity
-219676
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-1010110
Annuals > 1 > cash Flow > depreciation
57423
Annuals > 1 > cash Flow > change In Working Capital
-
Annuals > 1 > cash Flow > cash From Operations
-574537
Annuals > 1 > cash Flow > capital Expenditures
20428
Annuals > 1 > cash Flow > cash From Investing
-20428
Annuals > 1 > cash Flow > cash From Financing
603481
Annuals > 1 > cash Flow > net Change In Cash
8516
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-
Annuals > 1 > ratios > PB
-
Annuals > 1 > ratios > ROE
459.8180957410004
Annuals > 1 > ratios > ROA
-141.310886468368
Annuals > 1 > ratios > FCF
-594965
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-8.313979486319555
Annuals > 1 > health Score
41
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
4.030938712194201
Profitability > metrics > ROA
2.3385729245849705
Profitability > metrics > Net Margin
0.1727030761741752
Profitability > final Score
41
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.7611078049100064
Risk > final Score
68
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.3525961609408435
Liquidity > metrics > Quick Ratio
1.871824597341497
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
19
Prev Profitabilities > 1
45
Prev Profitabilities > 2
100
Prev Risks > 0
50
Prev Risks > 1
38
Prev Risks > 2
50
Prev Liquidities > 0
90
Prev Liquidities > 1
85
Prev Liquidities > 2
91
Updated At
2026-01-20T21:59:39.540Z
Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2010-09-30)
Health Score
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Hard to Treat Diseases Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2010-09-30)
(Last Updated 2010-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2010-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2010-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.